bmiMD vs. Calibrate: prices, fine print, and the honest verdict

Tirzepatide pricing

bmiMD does not offer tirzepatide. Calibrate offers tirzepatide without a published price we could capture.

Semaglutide pricing

Only bmiMD publishes a semaglutide price here: Semaglutide runs $289 a month all-in. Calibrate offers semaglutide without a published price.

Different products, not just different prices

Calibrate fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while bmiMD sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

bmiMD: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. Calibrate: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

bmiMD: none stated; not published. Calibrate: annual program; program terms apply.

The semaglutide board

Only bmiMD fields a verified semaglutide price here — $289/month all-in (#15 of 19) — while Calibrate routes semaglutide demand to brand Wegovy at $349 flat. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.

The five normalizations, applied to this pair

1 · All-in, not advertised. bmiMD publishes no figure to normalize; Calibrate bills at manufacturer/insurance rates plus any stated program fee. 4 · Evidence tiered. bmiMD: source-verified, read 2026-08-08; Calibrate: no price published, read 2026-08-05. 5 · Pharmacy weighed. bmiMD names no pharmacy; Calibrate names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

bmiMD: no membership — the medication figure is the billed figure; not published; commitment: none stated. Calibrate: no membership — the medication figure is the billed figure; program terms apply; commitment: annual program. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

bmiMD carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Calibrate carries no price published pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: bmiMD: shipping included; consultation included; async visit model. Calibrate: shipping per pharmacy; consultation program-based coaching; video visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick bmiMD if its published terms happen to fit your state, format, or timing. Pick Calibrate if only the FDA-approved product will do; you want the insurance paperwork done for you. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Calibrate, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Widen the frame one step and the strongest adjacent options are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

This one is a product decision more than a price decision — cheapest-possible compounded versus FDA-approved brand. Both records, with dates and sources, live in the pricing database.